| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b5d8ccf4f36e520cf10250925ddffe4e |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-71
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2863
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57492
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-71 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-475
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7088 |
| filingDate |
2005-10-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5b1efb551c7b329dbfe4f00776869e54 |
| publicationDate |
2008-06-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2008145369-A1 |
| titleOfInvention |
Autocrine Growth Factor Receptors and Methods |
| abstract |
Embodiments of the invention provide methods and compositions for method for diagnosing and treating diseases including cancer. In one embodiment diagnosing tumorigenicity is accomplished by measuring the level of PCDGF receptor expression in a tissue sample suspected of being tumorigenic. In another embodiment, a determination of whether tumorigenic cells will be responsive to an anti-PCDGF therapy is accomplished by determining whether there is a measured level of PCDGF receptor in a tissue sample suspected of being tumorigenic. In yet another embodiment, a method for treating a subject having a disease related to the amplification or overexpression of PCDGF includes administering a PCDGF receptor or fragment thereof to a patient in amounts effective to inhibit the biological activity of PCDGF. The invention also provides isolated PCDGF receptor nucleic acid molecules and proteins encoded by the PCDGF receptor nucleic acid molecules. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8911950-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7815906-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8088373-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2009010931-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7651854-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2008311120-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2007015225-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010111928-A1 |
| priorityDate |
2004-10-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |